Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ledipasvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ledipasvir SCHEMBL19981366 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL13071154 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL205601 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL19087952 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL2708471 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL18462701 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL18463016 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL19981367 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL18462752 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 | |
| Ledipasvir SCHEMBL15443804 | 1.00 | CYP2C9 (0.44) | CYP2C9CYP3A4NR1I2KCNH2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262793-B1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | MARCHINI ANTONIO (BE) | 2025-02-05 | — | — | EP | claimed |
| US-20240041833-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | Marchini, Antonio (BE) | 2024-02-08 | — | — | US | claimed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4262793-B1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | MARCHINI ANTONIO (BE) | 2025-02-05 | — | — | EP | disclosed |
| US-20250032484-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER | US GOV VETERANS AFFAIRS (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4440567-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER | The United States Government as represented by the Department of Veterans Affairs (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024110994-A1 | A PROCESS FOR THE PREPARATION OF LEDIPASVIR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2024-05-30 | — | — | WO | disclosed |
| US-20240041833-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | Marchini, Antonio (BE) | 2024-02-08 | — | — | US | disclosed |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230285435-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | disclosed |
| US-8273341-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| WO-2012087596-A1 | COMBINATIONS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110306541-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306541-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CYP2C9 3695/4885CYP3A4 2756/4885NR1I2 3001/4885 |
| US-20230285435-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | EIF2AK2, RNGTT, ADAR | CYP2C9 4741/4885CYP3A4 4445/4885NR1I2 4353/4885 |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | CYP2C9 3710/4885CYP3A4 3014/4885NR1I2 1985/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP2C9 3296/4885CYP3A4 1770/4885NR1I2 3435/4885 |
| US-20240041833-A1 | PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PROTOPARVOVIRUS AND AN ANTIVIRAL BENZIMIDAZOLE AND USES THEREOF FOR TREATING CANCER | PAICS, PKD1, PPA1 | CYP2C9 394/4885CYP3A4 43/4885NR1I2 2389/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | CYP2C9 3888/4885CYP3A4 3314/4885NR1I2 2676/4885 |
| US-11773098-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR6 | CYP2C9 4815/4885CYP3A4 3572/4885NR1I2 737/4885 |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CYP2C9 3296/4885CYP3A4 1770/4885NR1I2 3435/4885 |
| US-20250032484-A1 | THERAPEUTIC TARGETS AND AGENTS FOR THE TREATMENT OF POSTTRAUMATIC STRESS DISORDER | SLC6A3, SLC6A4, TMPRSS4 | CYP2C9 2311/4885CYP3A4 662/4885NR1I2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.